A Case of Surgical Resection in Hepatocellular Carcinoma with Pulmonary Metastasis |
Woo Jin Jung1, Jae Young Jang1, Jun Seok Park1, Hee Jeong Lee1, Young Kyu Cho1, Soung Won Jeong1, Sae Hwan Lee2, Snag Gyune Kim3, Sang Woo Cha1, Young Seok Kim3, Young Deok Cho1, Hong Soo Kim2, Boo Sung Kim1 |
1Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea 2Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine,Cheonan, Korea 3Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine,Bucheon, Korea |
Correspondence:
Jae Young Jang, Email: jyjang@schmc.ac.kr |
|
Abstract |
Hepatocellular carcinoma (HCC) is well known malignancy with poor prognosis, even after
resection of the primary tumor. Sorafenib is the first-line treatment in advanced HCC, but the
disease control rate of sorafenib is only 43%. Pulmonary metastasectomy in patients with
pulmonary metastasis from HCC has been reported to increase long-term survival compared
with systemic chemotherapy. Video-assisted thoracic surgery is considered a reliable
approach to the diagnosis and treatment of pulmonary diseases with low complication
rate. Pulmonary metastasectomy is not universally accepted because of frequent local
recurrence, an uncontrollable primary tumor, and frequent multiple pulmonary metastases
in HCC, but outcome of pulmonary metastasectomy and adjuvant sorafenib therapy has
not been studied. We experienced a patient who had advanced HCC with pulmonary
oligometastasis and received surgical resection of the metastatic pulmonary nodule and
sorafenib chemotherapy. In advanced HCC with pulmonary oligometastasis, surgical
resection of pulmonary metastasis and sorafenib chemotherapy should be considered. |
Key Words:
Hepatocellular carcinoma; Metastasis; Metastasectomy; Sorafenib |
NULL |
|